Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners
Open accessAbstract
Introduction: Collagenase Clostridium histolyticum (CCH) intralesional injection was efficacious for the management of Peyronie's disease (PD) in the double-blinded, randomized, placebo-controlled Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies I and II (IMPRESS I and II). Little is known about the consequences of PD or treatment on the sexual partners of affected men. Aim: To assess the safety and efficacy of CCH treatment in men who received placebo in the IMPRESS I or II study and to evaluate the men's PD symptoms and partner bother as reported by female sexual partners. Methods: In this phase 3, open-label study (NCT01685437), men (n = 189) received up to eight injections of CCH (0.58 mg/injection). Female sexual partners who provided informed consent at screening (n = 30) participated in the study. Main Outcome Measures: Co-primary end points were change or percentage of change in penile curvature deformity and change in PD symptom bother domain score of the Peyronie's Disease Questionnaire (PDQ) from baseline to week 36. Participating women completed the PDQ for female sexual partners (PDQ-FSP) and the Female Sexual Function Index (FSFI). Results: Statistically significant mean improvements were observed in penile curvature deformity (36.3% decrease; 95% CI = −41.6 to −30.9) and PDQ symptom bother score (2.4-point decrease; 95% CI = −3.0 to −1.8) from baseline to week 36. Most treatment-emergent adverse events were mild or moderate. After CCH treatment of their male partners, female sexual partners reported improvement (using the PDQ-FSP) in their male partner's PD symptoms and female bother regarding their partner's PD. The percentage of female sexual partners with sexual dysfunction (FSFI total score ≤ 26.55) also decreased after male partner treatment, from 75.0% at baseline to 33.3%. Conclusions: These results support the safety and efficacy of CCH in the management of appropriate patients with PD and the potential benefits for patients' partners. Goldstein I, Knoll LD, Lipshultz LI, et al. Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Partners and Their Female Partners. Sex Med 2017;5:e124–e130.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The PDQ bother mean score was 8.8, slightly higher than the 6.3-8.0 reported by other authors.
“In our research, we also found a slightly higher psychosexual impact (PDQ bother mean score = 8.8) compared to those reported by other authors (6.3–8.0) [60,64,83].”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 29 · Cited by 33
Research works printed but not linked: 17
- [2]Herati A.S. Pastuszak A.W. The genetic basis of Peyronie disease: a review Sex Med Rev 4 2016 85 94 PMC4778255 27872008
- [4]Rosen R. Catania J. Lue T. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls J Sex Med 5 2008 1977 1984 18564146
- [5]Smith J.F. Walsh T.J. Conti S.L. Risk factors for emotional and relationship problems in Peyronie's disease J Sex Med 5 2008 2179 2184 18638001 PMC2881678
- [6]Nelson C.J. Mulhall J.P. Psychological impact of Peyronie's disease: a review J Sex Med 10 2013 653 660 23153101
- [8]Yang K.K. Bennett N. The history of collagenase Clostridium histolyticum Sex Med Rev 3 2015 289 297 27784601
- [9]Gelbard M. Goldstein I. Hellstrom W.J. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies J Urol 190 2013 199 207 23376148
- [12]Rosen R. Brown C. Heiman J. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function J Sex Marital Ther 26 2000 191 208 10782451
- [13]Rosen R.C. Riley A. Wagner G. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822 830 9187685
- [14]Ralph D. Gonzalez-Cadavid N. Mirone V. The management of Peyronie's disease: evidence-based 2010 guidelines J Sex Med 7 2010 2359 2374 20497306
- [16]Levine L.A. Goldman K.E. Greenfield J.M. Experience with intraplaque injection of verapamil for Peyronie's disease J Urol 168 2002 621 625 discussion 625–626 12131321
- [17]Hellstrom W.J. Kendirci M. Matern R. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease J Urol 176 2006 394 398 16753449
- [18]Inal T. Tokatli Z. Akand M. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study Urology 67 2006 1038 1042 16581113
- [19]Levine L.A. Cuzin B. Mark S. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study J Sex Med 12 2015 248 258 25388099
- [20]Kadioglu A. Tefekli A. Usta M. Surgical treatment of Peyronie's disease with incision and venous patch technique Int J Impot Res 11 1999 75 81 10356666
- [21]Lopes I. Tomada N. Vendeira P. Penile corporoplasty with Yachia's technique for Peyronie's disease: single center experience with 117 patients Urol Ann 5 2013 167 171 24049379 PMC3764897
- [22]Usta M.F. Bivalacqua T.J. Sanabria J. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease Urology 62 2003 105 109 12837432
- [24]Rosen R. Janssen E. Wiegel M. Psychological and interpersonal correlates in men with erectile dysfunction and their partners: a pilot study of treatment outcome with sildenafil J Sex Marital Ther 32 2006 215 234 16809250
- Authors
- Goldstein, I., Knoll, L. D., Lipshultz, L. I., Smith, T., Kaufman, G. J., & McMahon, C. G.
- Affiliations
- Sexual Medicine , San Diego, CA, USA
- Center for Urological Treatment , Nashville, TN, USA
- Baylor College of Medicine (US)
- Endo Pharmaceuticals (United States) (US)
- Auxilium Pharmaceuticals , Malvern, PA, USA
- Australian Centre for Sexual Health (AU)
- Corresponding author
- Goldstein, Irwin
- Venue
- Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-05
- Volume
- 5
- Issue
- 2
- Pages
- e124-e130
- ISSN
- 2050-1161 (ISSN-L)
- PMC
- PMC5440642
- OpenAlex
- W2605253396
- Cited by
- 33
- References
- 29
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 2
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Sexual Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Auxilium Pharmaceuticals
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Keywords
- Peyronie's disease, collagenase clostridium histolyticum, intralesional injection, female sexual partners, sexual dysfunction, Peyronie's Disease Questionnaire, treatment efficacy and safety, Female Sexual Function Index, treatment-emergent adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
